JP2009502937A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009502937A5 JP2009502937A5 JP2008524094A JP2008524094A JP2009502937A5 JP 2009502937 A5 JP2009502937 A5 JP 2009502937A5 JP 2008524094 A JP2008524094 A JP 2008524094A JP 2008524094 A JP2008524094 A JP 2008524094A JP 2009502937 A5 JP2009502937 A5 JP 2009502937A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- compound
- kinase
- abl kinase
- mutant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091000080 Phosphotransferase Proteins 0.000 claims 10
- 102000020233 phosphotransferase Human genes 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 7
- 102000001253 Protein Kinase Human genes 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 108060006633 protein kinase Proteins 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70277105P | 2005-07-26 | 2005-07-26 | |
| US78516106P | 2006-03-23 | 2006-03-23 | |
| US83025706P | 2006-07-12 | 2006-07-12 | |
| PCT/US2006/028984 WO2007014250A2 (en) | 2005-07-26 | 2006-07-26 | Abl kinase inhibition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012122081A Division JP2012158616A (ja) | 2005-07-26 | 2012-05-29 | Ablキナーゼ阻害 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009502937A JP2009502937A (ja) | 2009-01-29 |
| JP2009502937A5 true JP2009502937A5 (cg-RX-API-DMAC7.html) | 2009-09-10 |
Family
ID=37683933
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008524094A Pending JP2009502937A (ja) | 2005-07-26 | 2006-07-26 | Ablキナーゼ阻害 |
| JP2012122081A Pending JP2012158616A (ja) | 2005-07-26 | 2012-05-29 | Ablキナーゼ阻害 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012122081A Pending JP2012158616A (ja) | 2005-07-26 | 2012-05-29 | Ablキナーゼ阻害 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090298844A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1906967A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2009502937A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006272609A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2616517A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007014250A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007065124A2 (en) * | 2005-12-01 | 2007-06-07 | Bristol-Myers Squibb Company | Methods of identifying and treating individuals exhibiting complex karyotypes |
| EP2051737A2 (en) * | 2006-07-26 | 2009-04-29 | Merck & Co., Inc. | A novel lactic acid formulation of mk-0457 useful for the treatment of cancer |
| SG11201406584TA (en) | 2012-04-24 | 2014-11-27 | Vertex Pharma | Dna-pk inhibitors |
| RS62649B1 (sr) | 2013-03-12 | 2021-12-31 | Vertex Pharma | Inhibitori dnk-pk |
| MY181020A (en) | 2013-03-15 | 2020-12-16 | Sanofi Sa | Heteroaryl compounds and uses thereof |
| TWI647220B (zh) | 2013-03-15 | 2019-01-11 | 美商西建卡爾有限責任公司 | 雜芳基化合物及其用途 |
| KR102411227B1 (ko) | 2013-10-17 | 2022-06-21 | 버텍스 파마슈티칼스 인코포레이티드 | Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정 |
| MA38393B1 (fr) | 2014-03-13 | 2018-11-30 | Sanofi Sa | Composés hétéroaryle et utilisations associées |
| MX394860B (es) | 2016-09-27 | 2025-03-24 | Vertex Pharma | Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk). |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2341133A1 (en) * | 2001-10-05 | 2011-07-06 | Novartis AG | Mutated Abl kinase domains |
| MY141867A (en) * | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| BRPI0515012A (pt) * | 2004-08-13 | 2008-07-01 | Genentech Inc | substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso |
-
2006
- 2006-07-26 EP EP06800350A patent/EP1906967A4/en not_active Withdrawn
- 2006-07-26 CA CA002616517A patent/CA2616517A1/en not_active Abandoned
- 2006-07-26 WO PCT/US2006/028984 patent/WO2007014250A2/en not_active Ceased
- 2006-07-26 AU AU2006272609A patent/AU2006272609A1/en not_active Abandoned
- 2006-07-26 JP JP2008524094A patent/JP2009502937A/ja active Pending
- 2006-07-26 US US11/989,300 patent/US20090298844A1/en not_active Abandoned
-
2012
- 2012-05-29 JP JP2012122081A patent/JP2012158616A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2869269C (en) | Use of ccr3-inhibitors | |
| CN103402514B (zh) | 用于治疗运动障碍的血清素受体激动剂组合物 | |
| JP2005506370A5 (cg-RX-API-DMAC7.html) | ||
| JP2013507415A5 (cg-RX-API-DMAC7.html) | ||
| NO20081843L (no) | Farmasoytisk sammensetning for forbedret kognitiv funksjon | |
| FI3952880T3 (fi) | 2-(2,6-dioksopiperidin-3-yyli)-4-((2-fluori-4-((3-morfolinoatsetidin-1-yyli)metyyli)bentsyyli)amino)isoindoliini-1,3-dioni käytettäväksi non-hodgkinin lymfooman hoidossa | |
| BRPI0506765A (pt) | composto ou um seu sal, hidrato e/ou pró-droga farmaceuticamente aceitáveis, composição farmacêutica, métodos para inibir a produção de beta-amilóide em um paciente e para tratar de uma doença, kit farmacêutico, uso de um composto ou de uma composição | |
| JP2010529118A5 (cg-RX-API-DMAC7.html) | ||
| EA201692214A1 (ru) | Вещества, связывающие ядерные рецепторы | |
| ITBO20110012A1 (it) | Composizioni farmaceutiche comprendenti rifaximina e loro uso. | |
| JP2019511489A5 (cg-RX-API-DMAC7.html) | ||
| WO2009066152A3 (en) | Haloallylamine inhibitors of ssao/vap-1 and uses therefor | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| JP2012508734A5 (cg-RX-API-DMAC7.html) | ||
| JP2018090566A5 (cg-RX-API-DMAC7.html) | ||
| JP2009062388A5 (cg-RX-API-DMAC7.html) | ||
| JP2009541409A5 (cg-RX-API-DMAC7.html) | ||
| JP2007501270A5 (cg-RX-API-DMAC7.html) | ||
| EA200800783A1 (ru) | Композиция тразодона для введения один раз в день | |
| NO20065152L (no) | Formulering med vedvarende frigivelse for oral administrering av HMG-COA-reduktaseinhibitor, og fremgansmate for fremstilling derav | |
| JP2008513426A5 (cg-RX-API-DMAC7.html) | ||
| JP2010539130A5 (cg-RX-API-DMAC7.html) | ||
| JP2008533021A5 (cg-RX-API-DMAC7.html) | ||
| CN109069466A (zh) | 5-ht6受体拮抗剂用于治疗阿尔茨海默病伴情感淡漠共病 | |
| ATE506941T1 (de) | Behandlung psychiatrischer patienten mit schlafstörungen und/oder übermässiger tagesschläfrigkeit mit paliperidon |